Stockscreener 앱 받기
2.30
4.17%
-0.10
전일 마감가:
$2.40
열려 있는:
$2.38
하루 거래량:
158.95K
Relative Volume:
0.54
시가총액:
$129.58M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
230.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
-3.77%
1개월 성능:
-3.36%
6개월 성능:
+25.68%
1년 성능:
+174.89%
1일 변동 폭
$2.28
$2.39
1주일 범위
$2.28
$2.41
52주 변동 폭
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.30 | 135.21M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Patterns Watch: Can Spero Therapeutics Inc ride the EV waveJuly 2025 Intraday Action & Stock Portfolio Risk Control - baoquankhu1.vn
Aug PostEarnings: Can Spero Therapeutics Inc sustain earnings growth2025 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
Valuation Update: Is Spero Therapeutics Inc stock showing strong momentum2025 Market Overview & Daily Volume Surge Signals - baoquankhu1.vn
Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock - simplywall.st
Is Spero Therapeutics Inc. a good stock for dollar cost averaging2025 Price Targets & Weekly High Potential Stock Alerts - mfd.ru
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha
Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock - MarketBeat
Keutzer, Spero Therapeutics COO, sells $44k in shares - Investing.com
Spero Therapeutics CEO sells $207k in stock By Investing.com - Investing.com Canada
Keutzer, Spero Therapeutics COO, sells $44k in shares By Investing.com - Investing.com Canada
Spero Therapeutics CEO sells $207k in stock - Investing.com
Aug Breakouts: What drives Spero Therapeutics Incs stock priceEarnings Summary Report & Safe Entry Zone Tips - baoquankhu1.vn
Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Spero therapeutics exec Rajavelu sells $40k in shares By Investing.com - Investing.com Australia
Spero therapeutics exec Rajavelu sells $40k in shares - Investing.com
Spero Therapeutics announces board resignation and SEC investigation closure By Investing.com - Investing.com Nigeria
Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks
SEC ends Spero Therapeutics (NASDAQ: SPRO) probe as director steps down - Stock Titan
SEC Enforcement Action Against Former Spero Executives: Individual Liability For Misleading FDA-Related Disclosures - marketscreener.com
SEC Enforcement Action against Former Spero Executives: Individual Liability for Misleading FDA-Related Disclosures - Foley & Lardner LLP
SEC Settlement Resolves Past Disclosure Issues for Spero Therapeutics - AD HOC NEWS
Spero Therapeutics announces inducement grant under Nasdaq listing rule - MSN
SEC Fines Biopharma Co. Execs Over Hidden FDA Findings - Law360
Momentum Shift: What is Spero Therapeutics Incs valuation compared to sector2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Insider Buy: Is Spero Therapeutics Inc stock overvalued by current metricsJuly 2025 EndofMonth & Low Drawdown Investment Ideas - Bộ Nội Vụ
Stock Market Recap: Will Spero Therapeutics Inc. stock reach all time highs in 20252025 Trading Volume Trends & Stock Portfolio Risk Management - Bộ Nội Vụ
Spero Therapeutics (NASDAQ:SPRO) Raised to "Buy" at Wall Street Zen - MarketBeat
Will Spero Therapeutics Inc. (2HA) stock sustain bullish trend into 2025 - ulpravda.ru
Is Spero Therapeutics Inc. (2HA) stock protected from inflationJuly 2025 Levels & Fast Gain Swing Trade Alerts - ulpravda.ru
Will Spero Therapeutics Inc. stock benefit from upcoming earnings reports2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
3 Promising Penny Stocks With Market Caps Up To $300M - simplywall.st
Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to Hold - MarketBeat
What analysts say about Spero Therapeutics Inc stockLong-Term Growth Stocks & Free Unmatched Market Gains - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Growth in Short Interest - MarketBeat
Book value per share of Spero Therapeutics, Inc. – BER:2HA - TradingView — Track All Markets
Spero Therapeutics (STU:2HA) EV-to-OCF : -2.75 (As of Dec. 24, 2025) - GuruFocus
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Growth Oriented Trade Recommendations - Улправда
Stop Loss: Will Spero Therapeutics Inc. stock reach all time highs in 2025Inflation Watch & Reliable Price Breakout Signals - ulpravda.ru
GSK, Spero Therapeutics resubmits NDA for tebipenem HBr as oral option for complicated urinary tract infections - Contemporary OB/GYN
GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks
Spero Therapeutics Announces NDA Resubmission for Tebipenem HBr - TradingView — Track All Markets
Spero Therapeutics Announces GSK's NDA Resubmission for Tebipenem HBr, Triggering $25 Million Milestone Payment - Quiver Quantitative
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to - GlobeNewswire
How geopolitical risks impact Spero Therapeutics Inc. (2HA) stockMarket Performance Report & Short-Term Trading Opportunity Alerts - DonanımHaber
Total debt per share of Spero Therapeutics, Inc. – FWB:2HA - TradingView — Track All Markets
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Spero Therapeutics Inc 주식 (SPRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Keutzer Timothy | Chief Operating Officer |
Feb 06 '26 |
Sale |
2.36 |
18,652 |
44,019 |
742,506 |
| Keutzer Timothy | Chief Operating Officer |
Feb 03 '26 |
Sale |
2.14 |
24,224 |
51,839 |
764,629 |
| Keutzer Timothy | Chief Operating Officer |
Feb 02 '26 |
Sale |
2.20 |
18,891 |
41,560 |
788,853 |
| Keutzer Timothy | Chief Operating Officer |
Feb 04 '26 |
Sale |
2.24 |
3,471 |
7,775 |
761,158 |
| Rajavelu Esther | See Remarks |
Feb 02 '26 |
Sale |
2.20 |
18,442 |
40,572 |
1,100,008 |
| Rajavelu Esther | See Remarks |
Nov 07 '25 |
Sale |
2.37 |
40,270 |
95,440 |
869,450 |
| Mahadevia Ankit | Director |
Aug 28 '25 |
Sale |
1.97 |
6,572 |
12,947 |
703,294 |
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
0.34%
0.89%
자본화:
|
볼륨(24시간):